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Hypoxia Contributes to Melanoma Heterogeneity by
Triggering HIF1a-Dependent Phenotype Switching
Daniel S. Widmer1, Keith S. Hoek1, Phil F. Cheng1, Ossia M. Eichhoff1, Thomas Biedermann2,
Marieke I.G. Raaijmakers1, Silvio Hemmi3, Reinhard Dummer1 and Mitchell P. Levesque1
We have previously reported a model for melanoma progression in which oscillation between melanoma cell
phenotypes characterized by invasion or proliferation is fundamental to tumor heterogeneity and disease
progression. In this study we examine the possible role of hypoxia as one of the microenvironmental influences
driving metastatic progression by promoting a switch from a proliferative to an invasive phenotype. Immuno-
histochemistry on primary human cutaneous melanoma biopsies showed intratumoral heterogeneity for cells
expressing melanocytic markers, and a loss of these markers correlated with hypoxic regions. Furthermore, we
show that the downregulation of melanocytic markers is dependent on hypoxia inducible factor 1a (HIF1a), a
known regulator of the hypoxic response. In vitro invasion assays showed that a hypoxic environment increases
the invasiveness of proliferative melanoma cell cultures in a HIF1a-dependent manner. In contrast, invasive
phenotype melanoma cells showed no increase in invasive potential upon exposure to hypoxia. Thus, exposure
of proliferative melanoma cells to hypoxic microenvironments is sufficient, in a HIF1a-dependent manner, to
downregulate melanocytic marker expression and increase their invasive potential.
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INTRODUCTION
Melanoma is a growing public health burden because it
is one of the few cancers still escalating in incidence
(Jemal et al., 2009). Despite advances in understanding the
molecular nature of melanoma in recent decades, few
treatment options are available for metastatic melanoma that
only marginally increase overall patient survival (Lui et al.,
2007; Bollag et al., 2010; Hodi et al., 2010; Joseph et al.,
2010; Chapman et al., 2011; Robert et al., 2011; Flaherty
et al., 2012). One reason why melanoma is difficult to treat is
its heterogeneity (Fidler, 1978). The source of this hetero-
geneity is unclear, but evidence suggests that it is driven by
microenvironmental factors (Postovit et al., 2006).
In the process of studying melanoma heterogeneity, we
described different subtypes of melanoma cells in vitro (Hoek
et al., 2006) that can be distinguished by gene-expression
analysis (Widmer et al., 2012). These differences in gene
expression correlate with alterations in in vitro cell morphol-
ogy, proliferation rate, invasion, transforming growth factor-b
susceptibility, and in vivo tumor growth kinetics (Hoek et al.,
2006; Hoek et al., 2008a). These experiments have identified
a proliferative phenotype and an invasive melanoma cell
phenotype. Previous work showed that primary and
metastatic lesions are commonly composed of a mixture of
both phenotypes (Eichhoff et al., 2010, 2011). We sub-
sequently hypothesized that melanoma cells, responding to
changes in microenvironmental conditions, change their
transcription programs to switch back-and-forth between
proliferative and invasive states and thereby drive metastatic
progression (Hoek et al., 2008a).
As other cancers, melanoma tumors include regions of
hypoxia and anoxia caused by an imbalance in both oxygen
supply and consumption. It has long been known that the
perfusion of tumors is heterogeneous resulting in a wide range
of pO2 levels both within and between tumors (Chaplin et al.,
1986). It is estimated that the proportion of solid tumors with
hypoxic (or anoxic) areas is up to 50–60% (Vaupel and Mayer,
2007). The negative impact of tumor hypoxia has been studied
extensively. Early studies have shown that hypoxia-induced
gene amplification can lead to resistance to treatment (Rice
et al., 1987; Luk et al., 1990). In many cancer types, the
induction of an epithelial-to-mesenchymal transition (EMT)-
like process by exposure to an intralesional hypoxic
microenvironment is currently under investigation. Tumor
hypoxia is known to reduce the sensitivity of solid tumors to
radiation therapy and can negatively influence treatment
outcome and patient survival in multiple cancer types
(Hockel et al., 1996; Vergis et al., 2008).
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Two recent studies of hypoxia in melanoma demonstrate a
role for hypoxia in downregulating the master regulator of
melanocyte differentiation, microphthalmia-associated tran-
scription factor (MITF). A study by Cheli et al. (2012) showed
that hypoxic conditions lead to a decrease in MITF expression
and that a deletion of MITF is sufficient to increase the
metastatic potential of mouse and human melanoma cells
in vivo. They identified BHLHE40 (BHLHB2, DEC1) as a
mediator of the observed hypoxia inducible factor 1a
(HIF1a)-dependent inhibitory effect on MITF. In another
study also published in 2011, the authors (Feige et al., 2011)
found BHLHE40 to be responsible for hypoxia-induced
downregulation of MITF.
To investigate the role of hypoxia in melanoma progression,
we describe the effects of hypoxia on proliferative and
invasive melanoma cell cultures. The results suggest that
hypoxia, through HIF1a, alters the gene-expression pattern
of proliferative melanoma cells, making them more invasive in
in vitro assays.
RESULTS
To gain more insight into the nature of intratumor heterogeneity
in patients, we stained Clark’s level IV primary human
cutaneous melanoma biopsies for key markers of melanocytic
function, hypoxia response, proliferation, and vascularization.
Immunohistochemical stainings show that the tumor is mostly
composed of tumor cell nodules (Figure 1a00–c00), which are
surrounded by stroma and endothelial cells (Figure 1c00, arrow-
heads). CD31 (PECAM-1), which is expressed constitutively on
the surface of adult and embryonic endothelial cells
(Pusztaszeri et al., 2006), was used to stain blood vessels.
Glucose transporter 1 (GLUT1) (SLC2A1), a glucose transporter
that has been shown to be upregulated in hypoxic tissue
(Bashan et al., 1992; Loike et al., 1992), was upregulated
with increasing distance from blood vessels in multiple regions
of the tumor (Figure 1c0, arrowheads). Panel a of Figure 1 shows
that the majority, but not all, of the cells in the tumor express
melanoma antigen recognized by T cells 1 (MLANA) that is
involved in melanosome biogenesis and has been widely used
to identify melanocytic lesions (Busam et al., 1998). In the
hypoxic areas, which are indicated by arrowheads in a0, we
found downregulation of the melanocytic marker MLANA
(Figure 1a0, arrowheads as compared with Figure 1b0) and
MITF (data not shown).To further illustrate the presence of
hypoxia in the tumor, we co-stained tumor slides for HIF1a and
GLUT1 (Supplementary Figure S2 online). As proliferative
phenotype cell cultures strongly express these melanocytic
markers, whereas invasive phenotype cell cultures do not
express them at all, their expression indicates a dedifferentia-
tion of the melanoma cells and points toward a gain of invasive
phenotype characteristics (Hoek et al., 2006, 2008a; Eichhoff
et al., 2010, 2011; Zipser et al., 2011). These data suggest that
by exposure to a hypoxic microenvironment, melanoma cells
downregulate melanocytic marker genes.
Hypoxia-regulated EMT genes are differentially expressed
between the two phenotypes
Intratumoral hypoxia has been shown to induce regulators of
EMT and metastasis in breast-, colon-, prostate-, and non-
small cell lung cancer (Luo et al., 2006; Peinado and Cano,
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Figure 1. Immunohistochemistry of a primary cutaneous melanoma. Overview pictures of a representative melanoma tumor are shown in the top row
(a, b, c); boxes on the right-hand side of a, b, and c indicate regions of higher magnification shown in a0, b0, and c0, and boxes on the left side highlight the
magnified region in a0 0, b0 0, and c0 0. Staining for MLANA (a, a0, and a0 0) shows regions with high expression and regions that have lost expression of this melanocytic
marker (arrowhead). GLUT1 (b, b0, and b0 0) stains hypoxic areas (arrowheads). CD31 shows blood vessels (c, c0, and c0 0, arrowheads). Scale bars¼ 3 mm (a),
500mm (b), and 500mm (c). MLANA, melanoma antigen recognized by T cells 1.
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2008; Hung et al., 2009; Jo et al., 2009; Sipos and Galamb,
2012). An expression analysis of some of the genes known
to be involved in this process shows a phenotype-specific
expression pattern (Supplementary Figure S1 online). LOX,
ZEB1, and MMP2, which are upregulated in the invasive
phenotype, have been shown to be involved in EMT, but also
in hypoxia-induced tumor invasiveness and metastasis (Ray
and Stetler-Stevenson, 1994; Postigo and Dean, 1997; Hojilla
et al., 2003; Stamenkovic, 2003; Erler et al., 2006; Peinado
et al., 2008; Spaderna et al., 2008; Baranwal and Alahari,
2009; Elloul et al., 2010; Jia et al., 2012; Xiong et al., 2012).
In development, as well as in the process of EMT and cancer
progression, E-cadherin (CDH1) is repressed and leads to a
loss of the extracellular matrix as well as of adherens and tight
junctions (Peinado et al., 2007). However, mesenchymal
cadherins, such as N-cadherin (CDH2), are upregulated
during EMT (Oda et al., 1998; Peinado et al., 2004). This
cadherin switch can also be observed in proliferative and
invasive melanoma phenotypes, with an upregulation of
CDH1 in proliferative cells and an upregulation of CDH2
in invasive cells (Supplementary Figure S1 online). These
findings suggest that an EMT-like process is involved in the
switching of melanoma cells from proliferative to invasive
phenotypes.
Hypoxia changes in vitro invasive potential in proliferative
melanoma cells in a dose-dependent manner
To further test if hypoxia drives proliferative cells to a more
invasive state, we treated proliferative phenotype cells with
1% O2 for 48 hours and tested their invasiveness in vitro
by performing Boyden chamber experiments. The prolifera-
tive cell cultures treated with hypoxia showed a significant
increase in invasion compared with the non-treated control
cells (Figure 2a). The relative invasion increased by 2-fold for
M080423, 2.3-fold for M000921, and even 4.2-fold for
M010817. However, invasive phenotype cells (i.e.,
M080307) in identical treatment conditions did not show
any change in invasiveness (P-value¼0.399) (Figure 2a). To
test if the gain of invasive ability required the continued
lack of oxygen, we returned the cells to normoxia for 48
hours after a hypoxia treatment period of 48 hours. In
Figure 2b (dark gray bar), we show that the effect remained
significant after cells were returned to normoxia 48 hours
before testing invasion. When the cells were exposed to
hypoxia for 96 hours, the effect was intensified (Figure 2b,
white bar). However, proliferative melanoma cells in hypoxic
conditions do not alter their proliferation rate (Supple-
mentary Figure S3 online).
Downregulation of MLANA during hypoxia is mediated by
HIF1a
The inverse correlation of hypoxic areas with the expression of
melanocytic markers like MLANA (Figure 1) raises the ques-
tion whether the decrease in the expression of this protein is
mediated by HIF1a, a known regulator of the hypoxic
response. To test this possibility, we treated proliferative
phenotype melanoma cells (i.e., M000921) with chemical
compounds to either suppress or activate signaling through
HIF1a. To inhibit HIF1a transcriptional activity, we treated the
cells with Echinomycin during exposure to hypoxia (1% O2
for 72 hours) (Kong et al., 2005). The induction of HIF1a as
well as the downregulation of MLANA could be inhibited
under hypoxia (Figure 3a), and the hypoxic induction of
in vitro invasion (Figure 2a) could be significantly abrogated
by about 8-fold through HIF1a knockdown (Figure 3b). The
same results on marker expression could be seen when we
enhanced HIF1a degradation with the chemical compound
YC-1 (Chun et al., 2001) (Figure 3c). CoCl2 stabilizes HIF1a by
inhibiting proline hydroxylases, leading to HIF1a expression
also under normoxic conditions (Epstein et al., 2001), leading
to downregulation of MLANA (Figure 3c). Because these
compounds might have off-target effects and because their
specificity is unclear, we also performed silencing RNA
(siRNA)-mediated knockdown of HIF1a using two different
siRNAs against the HIF1a transcript (Figure 3d). The results
confirm a HIF1a-dependent downregulation of MLANA in
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Figure 2. Hypoxia increases in vitro invasion in proliferative melanoma cells.
In vitro invasiveness of proliferative (M080423, M010817, and M000921) and
invasive (M080307; P-value¼0.399) phenotype melanoma cell cultures (a).
Hypoxia treatment of a proliferative melanoma cell culture (M080423) induces
increased invasiveness in a dose-dependent fashion (b). Light gray bar:
incubated in normoxia for 48 hours and subsequently analyzed in a Boyden
chamber assay in hypoxia for 48 hours; dark gray bar: vice versa. The P-values
are calculated by a t-test; the error bars represent the s.d.
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hypoxia, as well as a HIFa-dependent hypoxic induction of
invasive properties, suggesting a role for HIF1a in the
phenotype switch induced by tumor hypoxia.
Hypoxia regulates a phenotype-specific gene set through HIF-1a
It is likely that there are intermediate factors acting down-
stream of HIF1a that repress MLANA gene expression. To find
HIF1a targets that might repress MLANA, we performed
siRNA knockdown of HIF1a followed by quantitative real-
time reverse-transcriptase–PCR (qRT-PCR) analysis. We tested
90 genes that have been previously identified to be differen-
tially expressed between a large number of proliferative and
invasive phenotype melanoma cell lines (Widmer et al.,
2012). These genes were assembled on a custom qRT-PCR
array. This array was used to find genes that are
downregulated when treated with hypoxia, but rescued
when HIF1a is knocked down. The results show 12 genes
that are at least 2-fold downregulated upon hypoxia treatment
(hypoxia sico) (Figure 4a) and at least 2-fold upregulated when
HIF1a was knocked down under hypoxic conditions (hypoxia
siHIF1a) compared with normal hypoxia (hypoxia sico).
Of the 12 genes, 8 were upregulated in the proliferative
phenotype cell cultures (Figure 4a, gene names in green) and
4 were upregulated in invasive phenotype cell cultures
(Figure 4a, gene names in red). We were also interested in
genes that were upregulated at least 2-fold upon hypoxia
treatment (hypoxia sico), but had an at least 2-fold decreased
expression when HIF1a is knocked down under hypoxic
conditions (hypoxia siHIF1a) compared with normal
hypoxia (hypoxia sico). Of the 12 genes fulfilling these
criteria, 10 were upregulated in the invasive phenotype cells
(Figure 4b, gene names in red), whereas 2 genes were
upregulated in the proliferative phenotype cell cultures
(Figure 4b, gene names in green). The results show that
18 (75%) out of the 24 genes regulated by HIF1a were
differentially regulated between the proliferative and invasive
melanoma cell lines in such a way that proliferative genes
were downregulated and invasive genes are upregulated by
HIF1a (i.e., genes with green text in Figure 4a, and genes with
red text in Figure 4b).
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Figure 3. Downregulation of MLANA and upregulation of in vitro invasion
upon hypoxia treatment is hypoxia inducible factor 1a (HIF1a) dependent.
Echinomycin enhances HIF1a degradation under hypoxic conditions (a).
Relative invasion under hypoxic culture conditions and treatment with silencing
RNA (siRNA) against HIF1a (Hyp siHIF1a) and control siRNA (Hyp siCo),
P-valueo0.05, done in quadruplicate (b). Treatment of proliferative melanoma
cell cultures with YC-1 decreases HIF1a levels. CoCl2 stabilizes HIF1a
under normoxic conditions (c). Under normoxia, no HIF1a could be
detected (d). Treatment with siRNA against HIF1a (siHIF1 a _5/_6) and
control siRNA (siControl). The P-value is calculated by a t-test; the error
bars represent the s.d. MLANA, melanoma antigen recognized by T cells 1.
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Figure 4. qRT-PCR using RNA from hypoxia- and/or siHIF1a-treated
proliferative phenotype melanoma cell cultures. Genes that were at least
2-fold downregulated when grown in a hypoxic environment (hypoxia sico),
but at least 2-fold upregulated when HIF1a was knocked down (hypoxia
siHIF1a) (a). Genes that were at least 2-fold upregulated when grown in a
hypoxic environment (hypoxia sico), but at least 2-fold downregulated when
HIF1a was knocked down. This experiment was performed in duplicates with
two different siRNAs against HIF1a (b). Gene names in green highlight
genes that were upregulated in the proliferative phenotype melanoma cell
cultures. Gene names in red indicate genes that were upregulated in the
invasive phenotype cell cultures.
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DISCUSSION
The characterization of different subsets of melanoma cells in
a tumor lesion is of major clinical relevance, because all the
subpopulations of melanoma cells need to be killed for
successful therapeutic intervention. The exceptional transcrip-
tional and phenotypic plasticity of melanoma cells has so far
hampered the discovery of single prognostic factors or target
molecules appropriate for general melanoma therapy. In our
previous work, we demonstrated that invasive phenotype
melanoma cells are less susceptible to MAPK inhibition and
that proliferative phenotype melanoma cells temporarily
switch their phenotype to one with more invasive features
during drug treatment (Zipser et al., 2011). Furthermore,
immunotherapy targeting melanocytic markers will not
eradicate the invasive phenotype cells, because these
markers are downregulated upon phenotype switching.
Recently published studies have shown inter- and intratu-
moral heterogeneity for driver mutations like BRAF or
KIT, suggesting a limited scope for current therapies in
personalized medicine that target specifically mutated serine
or tyrosine kinases (Sakaizawa et al., 2012; Yancovitz et al.,
2012). Not only is intrinsic genetic heterogeneity of impor-
tance as a basis for tumor progression, but acquired
heterogeneity that is induced by microenvironmental factors
may also lead to therapeutic resistance. To overcome intrinsic
as well as acquired resistance, it is imperative to understand
tumor heterogeneity at the genetic and transcriptional levels.
We have previously shown that melanoma cells with high
MITF and MLANA expression are only weakly invasive
in vitro, whereas melanoma cells with no MITF and MLANA
expression are highly invasive (Hoek et al., 2006; Eichhoff
et al., 2011; Zipser et al., 2011). Immunohistochemical
stainings of melanoma tumors show regions with high
GLUT1 expression, indicating hypoxic regions which anti-
correlate with the melanocytic markers MITF and MLANA
(Figure 1). These results suggest that in a hypoxic microenvir-
onment, melanocytic markers are downregulated, which is a
sign of cell dedifferentiation that is also evident in invasive
phenotype cells. These data confirm the results of an earlier
study in which proliferative markers (i.e., MLANA and MITF)
were anti-correlated with invasive markers (WNT5A) and
hypoxia (GLUT1) in melanoma (Eichhoff et al., 2010).
Conversely to what Eichhoff et al. reported, we also
observed GLUT1 expression in many nested, nicely
organized tumor regions (Figure 1). Although the staining for
CD31 suggests the presence of blood vessels around the tumor
cell nests, it seems that either the nests are too large or the
blood vessels are not fully functional so that the melanoma
cells become hypoxic.
To identify the role that hypoxia might have in melanoma
progression, we measured the effect of hypoxic conditions on
the in vitro invasive potential of proliferative melanoma cells
by performing Boyden chamber invasion assays. The results
showed a significant increase in invasion from 2- to more than
4-fold for all tested proliferative cell cultures (Figure 2a). An
invasive cell line (i.e., M080307) did not display such an
increase in invasive potential (Figure 2a). We also showed that
the higher in vitro invasiveness observed in proliferative
melanoma cultures is dose dependent, lasts at least 48 hours,
and increases with longer exposure time up to 96 hours
(Figure 2b).
Because one of the mediators of hypoxic responses in many
cell types is the HIF1a protein, we modulated its expression
level and could show that the hypoxic downregulation of
MLANA is HIF1a dependent (Figure 3). We demonstrate that
a knockdown of HIF1a under hypoxic conditions decreases
in vitro invasion by about 8-fold, thereby suggesting
a requirement for HIF1a in the hypoxic-induced invasive
ability of proliferative melanoma cell cultures (Figure 3b).
Possible mediators for this effect were identified by qRT-PCR
analysis of 90 genes, which are differentially expressed
between the proliferative and invasive melanoma phenotypes
(Widmer et al., 2012). Analysis of these data showed 12 genes
to be downregulated by hypoxia treatment, but not when
HIF1a is knocked down (Figure 4). Of these, eight genes are
commonly downregulated in the invasive melanoma cell
cultures and therefore potentially involved in the switch from
a proliferative to an invasive phenotype. Interestingly, MITF
and its target tyrosinase-related protein 1are among these
genes (Figure 4). Also, TNFRSF14, CAPN3, GPM6B, and
DAPK1, which are potential targets of MITF that we have
previously identified (Hoek et al., 2008b), are differentially
expressed. This suggests an important role for HIF1a-regulated
MITF in the process of hypoxia-induced phenotype switching.
Furthermore, two of these genes are known to have a pro-
apoptotic function: calpain 3 (CAPN3) (Moretti et al., 2009)
and death-associated protein kinase 1 (DAPK1) (Lin et al.,
2007). In addition, glycoprotein M6B (GPM6B) has been
shown to be downregulated in highly invasive melanoma
cells versus poorly invasive lines (Seftor et al., 2002).
Furthermore, a set of 12 genes is induced by hypoxia but
not when HIF1a is knocked down (Figure 4). Ten of these
genes are upregulated in the invasive phenotype melanoma
cell cultures and are therefore of particular interest
(Figure 4). One of the most interesting genes encodes
fibroblast growth factor 2, a mitogenic and angiogenic factor
that can act as an autocrine growth factor for melanoma cells
(Halaban et al., 1988; Becker et al., 1989). AXL, a receptor
tyrosine kinase, has been shown to be expressed only in
MITF-negative melanoma cells (Sensi et al., 2011), confirming
our own results (Hoek et al., 2006; Widmer et al., 2012).
Sensi et al. also showed that AXL increases the motility
and invasion of melanoma cells. HIF1a appears also
to induce the expression of multiple genes that encode
proteins involved in interactions with the extracellular
matrix, such as ADAM12, a disintegrin and metalloprotei-
nase (COL13A1), a transmembrane collagen chain (ITGA3),
an integrin alpha subunit, and FLNB, a filamin known to bind
to the actin cytoskeleton (Prockop and Kivirikko, 1995;
Takafuta et al., 1998; Danen and Sonnenberg, 2003;
Lendeckel et al., 2005; Kveiborg et al., 2008). The
upregulation of BIRC3, a gene encoding an apoptosis
inhibitor, is consistent with the downregulation of two pro-
apoptotic genes (CAPN3 and DAPK1). The potassium channel
KCNMA1, which is also upregulated in the presence of
hypoxia in a HIF1a-dependent manner, could be regulated
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by MITF over the microRNA miR-211 (Mazar et al., 2010).
Further studies have to determine if inhibition of one or
more of these factors can abrogate the tumor-promoting
effect of HIF1a.
The data presented here suggest that hypoxia is a possible
microenvironmental stimulus triggering a switch from a pro-
liferative to an invasive melanoma cell phenotype. By down-
regulating melanocytic genes, HIF1a induces an EMT-like
dedifferentiation to a more invasive type of melanoma cell.
Upregulation of pro-angiogenic and pro-tumorigenic factors,
as well as of extracellular matrix-modifying genes along with a
downregulation of pro-apoptotic genes, may allow the inva-
sive melanoma cells to contribute to melanoma progression.
MATERIALS AND METHODS
Cell culture
M-series primary melanoma cell cultures were set up from surplus
material from cutaneous melanoma and melanoma metastases in our
laboratory. Many of these lines have been previously published and
have been shared with multiple international laboratories for in vitro,
genomic, and xenografting assays (Lin et al., 2008; Hoek et al.,
2008a; Eichhoff et al., 2011; Zipser et al., 2011; Kiowski et al., 2012;
Widmer et al., 2012). Written informed consent was approved by the
local IRB (EK647 and EK800). Clinical diagnosis was confirmed by
histology and immunohistochemistry. Melanoma cells were brought
into culture as previously described (Geertsen et al., 1998).
Melanoma cell cultures were grown in RPMI (Invitrogen, Carlsbad,
CA) including 5 mM glutamine, 1 mM sodium pyruvate, and 10% heat-
inactivated fetal bovine serum (GIBCO 10500; Invitrogen), and they
were grown at 37 1C and 5% CO2. The study was conducted
according to the Declaration of Helsinki Pinciples.
Quantitative real-time reverse-transcriptase–PCR
Total RNA was extracted from primary melanoma cell cultures using
TRIzol according to the manufacturer’s instructions (Invitrogen). Total
RNA was used for cDNA synthesis using Promega’s Reverse Tran-
scription System (Promega, Madison, WI) or RT HT First Strand cDNA
kit for the qRT-PCR arrays according to the supplied protocols. Gene
expression was quantified using the FastStart Universal SYBR Green
Master (ROX; 04913914001; Roche, Basel, Switzerland) and the Viia7
system from Applied Biosystems (Carlsbad, CA). The primers for MITF
and WNT5A were purchased from Qiagen (Venlo, the Netherlands).
The qRT-PCR arrays (Custom RT2 Profiler PCR Array (CAPH10586E-6))
were purchased from SA Biosciences (Qiagen, Venlo, the Netherlands).
Western blot analyses
Cells were washed twice with cold phosphate-buffered saline and
lysed at 4 1C in RIPA protein lysis buffer as previously reported
(Dissanayake et al., 2007). Proteins were separated by SDS-PAGE
using the NuPAGE SDS-PAGE Gel System (Invitrogen) on 4–12% Tris-
glycine gels (Invitrogen) under reducing conditions according to the
manufacturer’s instructions and transferred onto nitrocellulose mem-
branes (Invitrogen). Primary antibodies used were: HIF1a: mouse
monoclonal anti-HIF1alpha 1:1000 (610959; BD Biosciences,
San Jose, CA); MLANA: mouse monoclonal anti-MLANA 1:1000,
(ab3168; Abcam, Cambridge, UK); ACTIN: goat polyclonal anti-Actin
1:1000 (sc-1616; Santa Cruz Biotechnology, Dallas, TX). Secondary
antibodies used were: rabbit polyclonal anti mouse IgG-HRP
(ab97046, Abcam) and Rabbit anti-goat IgG-HRP (sc-2768, Abcam).
Bound antibodies were detected using ECL Western Blotting Detec-
tion Reagent (28906836; GE Healthcare).
In vitro invasion assay (Boyden chamber assays)
In vitro invasion assays were performed using Matrigel-coated cell
inserts (BD Biosciences; 354480) and uncoated cell inserts (BD
Biosciences; 353097) according to the manufacturer’s instructions.
A total of 5 104 cells in 500ml starving medium were seeded onto
cell culture inserts. RPMI containing 10% fetal calf serum was used as
chemoattractant. After incubation at 37 1C for 48 hours, the cells on
the membranes were fixed, stained, cut out, and mounted on a glass
slide. The number of cells, which had moved through the pores to the
other side of the membrane, was assessed by microscopy. Invasion
values were calculated by dividing the number of cells migrating
through Matrigel-coated inserts by the number of cells migrating
through uncoated inserts.
Proliferation assay
Melanoma cells were counted after 24, 48, and 72 hours, and
doubling time was calculated.
Immunohistochemical stainings
All tissue used for immunohistochemistry was fixed in 4% parafor-
maldehyde and embedded in paraffin. Sections were deparaffinized
in xylene and rehydrated. Epitope retrieval was performed in antibody
specific buffers. Staining was performed using kits supplied by
Ventana (Tucson, AZ) or Dako (Glostrup, Denmark) REAL Detection
System (kit 5005). Antigen-specific antibodies were applied and
visualized with either the iVIEW DAB detection kit (Ventana) or the
Chem-Mate detection kit (Dako). Slides were counterstained with
haematoxylin. Antibodies used were: MLANA (Novocastra, Leica
Biosystems, Nussloch, Germany; NCL-L-MLANA; EDTA; 1:50),
GLUT1 (Cell Marque, Rocklin, CA; 355A-16; EDTA; 1:100), CD31
(Dako; M0823; Protein kinase K; 1:40), and Hif1alpha (Abcam; mgc3,
ab16066).
Hypoxia treatment
Cells were cultured in a Modular Incubator Chamber (MIC-101;
Billups-Rothenberg, Del Mar, CA), flushed with 20 l min 1 (flow
meter; RMA-23-SSV; Dwyer, Michigan City, IN) with certified pre-
mixed gas composed of 1% O2, 5% CO2, and 94% N2 (Carbagas,
Guemligen, Switzerland). The O2 concentration inside the chamber
was measured with an oxygen sensor (VTI-122, Disposable Polaro-
graphic Oxygen Cell, 100122; Vascular Technology, Nashua, NH).
The hypoxia chamber was placed in an incubator at 37 1C. Medium
exchange and splitting of the cells was performed outside the hypoxic
environment. To stabilize HIF1a expression in melanoma cells under
normoxic conditions, cells were treated with 100mM CoCl2 (Sigma-
Aldrich, St Louis, MO) for 24, 48 or 72 hours. To inhibit expression or
stabilization of HIF1a in melanoma cells under hypoxic conditions,
cells were treated with 60mM YC-1 (Calbiochem, Merck, Darmstadt,
Germany) or 5 nM of Echinomycin Streptomyces sp (Calbiochem).
siRNA transfections
siRNA transfection of melanoma cells was carried out using INTER-
FERin transfection solution according to the manufacturer’s protocol
(Polyplus Transfection, Illkirch, France). Cells were transfected with
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10 nM of siRNA (Qiagen) for 24, 48 or 72 hours before RNA or protein
was extracted. As control siRNA, the All-Star negative siRNA
sequence (Qiagen) was used. siRNA used were: Hs_HIF1A_5
(NM_001530; S102664053, Qiagen FlexiTube) and Hs_HIF1A_6
(NM_001530; S102664431, Qiagen FlexiTube).
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